An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

The HealthCare segment at Bayer (BAYRY) announced that it has submitted a Marketing Authorisation Application for Eylea (aflibercept solution) for the treatment of patients suffering from visual ...

Jan 13 (Reuters) - U.S. based-Regeneron Pharmaceuticals Inc and Germany's Bayer AG said they would co-develop an antibody for use in combination with Eylea, their treatment for a form of age ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

May 23, 2025 Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

On the surface, macular degeneration treatment Eylea continued its juggernaut path in 2022. On Tuesday, when Bayer reported fourth quarter earnings, it showed 3.2 billion euros ($3.4 billion ...

But while the New York company has felt the effects of the competition acutely, Bayer—which commercializes Eylea outside of ... Sales of kidney disease treatment Kerendia reached 85 million ...

Bayer and Regeneron have expanded their eyecare collaboration to include the development of a second treatment for wet age-related macular degeneration (AMD). The partners already market Eylea ...

FRANKFURT, Sept 8 (Reuters) - Bayer (BAYGn.DE), opens new tabsaid on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), opens new tab, has been shown to work ...

Bayer has licensed exclusive marketing rights outside the United States, where the companies share equal profits from the sales of Eylea. Eylea’s intravitreal injection 40 mg/mL has been approved for ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).